Agilent LC system targets biologically active substances

Biologically active substances can be identified and characterised using a liquid chromatography (LC) system developed by Agilent Technologies.

The company's newly launched 1260 Infinity bio-inert quaternary LC system offers the highest resolution per time of any current bio-inert bioseparation method based around LC, the firm says.

By combining a 600-bar power range with a standard detector, it also promises low limits on detection.

Agilent LC marketing director Stefan Schuette says: "This new system is a complete solution for addressing the growing demand to analyse new biological entities and biosimilars."

This need arises from drug developers' desire to demonstrate the efficacy and safety of biologically active substances, he adds.

A key element in improving the design over previous similar LC systems is the elimination of iron and steel from the solvent delivery process.

This, Agilent explains, means there are fewer surface interactions when analysing biomolecules, as well as extending column lifespan.